Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the JDRF lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Your donations help support people living with type 1 diabetes today and fund the best treatment and cure research, no matter where in the world it takes place.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
The focus of this event is ‘type 1 technology’ covering aspects such as access, choice, and everyday living with type 1 technology.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > About JDRF & our impact > Our research > Information for researchers > Current research funding opportunities > International JDRF funding opportunities
We offer a wide range of funding schemes for researchers in the field of type 1 diabetes and its associated complications, including Strategic Research Agreements, Industry Discovery and Development Partnerships, Innovative Grants and conference grants. We also offer training grants including postdoctoral fellowships, advanced postdoctoral fellowships, career development awards, early-career patient-orientated diabetes research awards and psychology fellowship awards.
The following JDRF funding opportunities are administered by our central office in New York. Read our guidance on applying for JDRF funding for more information about the application process.
Funding for single or multiple investigators to address critical gaps and challenges and potential breakthroughs in type 1 diabetes research. The Strategic Research Agreement (SRA) is a partnership between researchers and JDRF scientists to help address roadblocks and accelerate JDRF’s mission through support of cutting-edge scientific investigation.
Read more about the Strategic Research Agreement and how to submit your Project Concept.
The next SRA deadline after this will be 5 November 2024 with a LOI status notification (contact by JDRF staff for further project development) of 13 December 2024.
We accept and review applications for funding opportunities in this section throughout the year.
Our industry partnerships aim to promote for-profit interest in JDRF’s mission to find a cure for type 1 diabetes and its complications, focusing on a priority area within JDRF’s mission. IDDP provides a mechanism and opportunity for JDRF to foster long-term collaborative relationships with industry, taking promising type 1 diabetes research through discovery and development and toward commercialisation.
This funding opportunity is aimed at biotechnology and pharmaceutical companies or other public or private for-profit organisations. We encourage applications from companies proposing collaboration with academic researchers.
For more information about this opportunity, including current and past partnerships, please visit our Industry Research Partnerships page.
We offer financial support for scientific meetings, conferences, and workshops relevant to JDRF’s mission of eradicating type 1 diabetes and its effects on people. Funding is provided for organisation and delivery of an event and does not provide individual support to an applicant for conference attendance.
You should submit your conference grant application three to six months prior to your proposed meeting date. Read more about our conference grants including eligibility criteria and how to apply.
These funding opportunities below have now closed but give you an idea of the type of research topics JDRF funds. You can also find details of key dates for when you will hear whether your application has been approved and when we expect the funded projects to start.
The aim of this call is advancing our understanding of glycaemic changes during disease progression in presymptomatic individuals (Stages 1 and 2), with the potential to improve progression biomarkers and monitoring their transition to clinical diagnosis (Stage 3).
The focus of this call is the improvement of current or new metabolic risk assessment tools and their integration into clinically and commercially utilized testing platforms.
Proposed budgets for projects should not exceed $900,000.00 total costs for up to 3 years of duration.
Read more about the glycaemic and beta cell monitoring in individuals at risk of type 1 diabetes call for applications.
JDRF will hold an announcement introduction meeting via Zoom on 20 December at 3-4pm GMT. Please register to this webinar using this link.
JDRF provides seed funding for highly innovative, high risk high reward research with significant potential to accelerate the mission of JDRF. Proposals should address key outstanding questions and have the potential to lead to a challenge or a change in the current paradigm or conventional wisdom and/or lead to a ground breaking discovery.
Innovative grants provide one year of support for a maximum of $200,000.00 which includes 10% indirect costs.
Read more about the Innovative Awards.
The goal of this funding opportunity is to accelerate the identification and validation of reagents that promote immune rebalance and the protection of beta cell function through modulating the trafficking of immune cells to the pancreatic islets.
Proposals submitted for this opportunity should describe the preclinical or clinical development of therapeutic strategies targeting the trafficking of disease-relevant immune cell populations.
This program will award grants of up to $900k over 3 years.
Read more about the development of interventions to modulate immune cell trafficking in T1D call for applications.
JDRF held an announcement introduction meeting via Zoom on 13 December at 9-10pm GMT.
The funding aims to support the implementation and integration of evidence based T1D specific behavioural and psychosocial interventions into clinical practice.
This program will award grants up to $1,500,000.00 over 4 years.
Read more about the effectiveness and implementation trials to address mental health in type 1 diabetes.
The funding aims to support the advancement of early preclinical stage hypoimmunogenic pluripotent stem cells (PSCs) for beta cell replacement in type 1 diabetes into late preclinical or pilot clinical testing.
The primary objective is to further develop established genetically modified beta/islet cells derived from PSCs with immune evasive properties through late preclinical validation, scaling, and clinical testing which will ultimately lead to type 1 diabetes therapies.
Read more about the Translation of hypoimmunogenic beta/islet cell sources into late preclinical/clinical testing for cell therapies in T1D.
This funding call is titled Accelerating Collaborative Research in Type 1 Diabetes Etiology and Pathogenesis using Biosamples from an Observational Clinical Study. It is open to researchers anywhere in the world.
The funding aims to support collaborations with ENDIA investigators to improve understanding of the etiology and pathogenesis of type 1 diabetes during gestation and early childhood.
This call seeks new collaborators outside of the current network of ENDIA investigators to carry out research using data and biosamples from ENDIA. Relevant proposals led by investigators whose expertise is not type 1 diabetes are also encouraged.
ENDIA will provide biosamples, relevant clinical metadata and additional support. JDRF Australia and Helmsley will provide funding to cover project activities.
Funding for single or multiple investigators to address critical gaps and challenges and potential breakthroughs in type 1 diabetes research. The Strategic Research Agreement is a partnership between researchers and JDRF scientists to help address roadblocks and accelerate JDRF’s mission through support of cutting-edge scientific investigation.
Our Small Grant Awards offer funding of up to £25,000 for a maximum of 12 months, for UK-based early career researchers.
Discover the opportunities for research projects funded in partnership with other organisations.
Learn more about how JDRF can help you to involve people with lived experience in your research.